Wheaton

Researchers are studying the dose-response effects of galvokimig compared with a placebo in adults with moderate-to-severe atopic dermatitis, a chronic skin condition lasting at least one year. The study focuses on adults aged 18 years and older who have significant disease activity as measured by specific clinical scores and a history of inadequate response to topical treatments or contraindications to them. This phase 2 trial aims to evaluate the safety, effectiveness, and how the drug behaves in the body. Participants will receive either galvokimig or a placebo as an injection. The study uses a randomized, double-blind, placebo-controlled design with multiple doses tested in parallel groups. Treatments are given as solutions for injection, and the study monitors participants over a defined period to assess how the drug works and its safety profile. During the study, participants will undergo assessments including clinical scoring of their skin condition such as the Eczema Area and Severity Index at week 16 to measure response. Researchers will also monitor safety through physical exams, laboratory tests, and medical history reviews. The study requires stopping other systemic or topical treatments before starting and tracks participant adherence and outcomes carefully throughout the study duration.

This research focuses on parents who have lost a child unexpectedly or traumatically, such as through suicide or overdose, and who often face serious mental and physical health challenges along with family disruptions. The trial examines two different ways to support these grieving parents, addressing the gap where medical examiners or coroners (MEs) typically have limited training and no standard guidelines for helping families during this difficult time. The goal is to identify which approach better connects parents to the care and resources they need after their child's death. The study compares two interventions delivered through a community organization called Missing Pieces. One intervention, CommunityRx-Bereavement (CRx-B), involves a Grief Navigator who contacts parents, provides personalized grief and social support resources, and maintains ongoing communication up to 12 months after the child's death. The other, General Bereavement Support Information (GBSI), sends parents text messages with links to general grief resources and information at multiple intervals up to 12 months post-loss. Parents will be asked to complete surveys about their experiences approximately 6.5 months after their child's death. Researchers will measure outcomes like how confident parents feel in finding support resources and levels of complicated grief. The study includes multiple sites and is designed as a randomized controlled trial to evaluate which method more effectively supports bereaved parents over time.